JPH0521089B2 - - Google Patents
Info
- Publication number
- JPH0521089B2 JPH0521089B2 JP62031233A JP3123387A JPH0521089B2 JP H0521089 B2 JPH0521089 B2 JP H0521089B2 JP 62031233 A JP62031233 A JP 62031233A JP 3123387 A JP3123387 A JP 3123387A JP H0521089 B2 JPH0521089 B2 JP H0521089B2
- Authority
- JP
- Japan
- Prior art keywords
- hypertension
- glucose
- antihypertensive
- therapeutic agent
- blood pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 claims description 14
- 206010020772 Hypertension Diseases 0.000 claims description 10
- 229940124597 therapeutic agent Drugs 0.000 claims description 9
- 230000003449 preventive effect Effects 0.000 claims description 6
- 150000002402 hexoses Chemical class 0.000 claims description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 239000011575 calcium Substances 0.000 claims description 4
- 229910052791 calcium Inorganic materials 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 description 9
- 229910000389 calcium phosphate Inorganic materials 0.000 description 8
- 230000003276 anti-hypertensive effect Effects 0.000 description 7
- 241000700159 Rattus Species 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000002220 antihypertensive agent Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940030600 antihypertensive agent Drugs 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 235000011010 calcium phosphates Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- -1 hexose calcium phosphate Chemical class 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 2
- 206010008635 Cholestasis Diseases 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- RPTUSVTUFVMDQK-UHFFFAOYSA-N Hidralazin Chemical compound C1=CC=C2C(NN)=NN=CC2=C1 RPTUSVTUFVMDQK-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229940121792 Thiazide diuretic Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 231100000359 cholestasis Toxicity 0.000 description 2
- 230000007870 cholestasis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 229960002003 hydrochlorothiazide Drugs 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 229940080360 rauwolfia alkaloid Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000003451 thiazide diuretic agent Substances 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YKFCISHFRZHKHY-NGQGLHOPSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)-2-methylpropanoic acid;trihydrate Chemical compound O.O.O.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1.OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 YKFCISHFRZHKHY-NGQGLHOPSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- LEROTMJVBFSIMP-UHFFFAOYSA-N Mebutamate Chemical compound NC(=O)OCC(C)(C(C)CC)COC(N)=O LEROTMJVBFSIMP-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- YKVGWOWERSDKRZ-ZQNYHYCUSA-H P(=O)([O-])([O-])[O-].[Ca+2].O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.P(=O)([O-])([O-])[O-].[Ca+2].[Ca+2] Chemical compound P(=O)([O-])([O-])[O-].[Ca+2].O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.P(=O)([O-])([O-])[O-].[Ca+2].[Ca+2] YKVGWOWERSDKRZ-ZQNYHYCUSA-H 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000489523 Veratrum Species 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 208000002353 alcoholic hepatitis Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 229940083181 centrally acting adntiadrenergic agent methyldopa Drugs 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 108091008690 chemoreceptors Proteins 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229940124567 diuretic antihypertensive agent Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 229960002474 hydralazine Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- BJHIKXHVCXFQLS-PQLUHFTBSA-N keto-D-tagatose Chemical compound OC[C@@H](O)[C@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-PQLUHFTBSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960004119 mebutamate Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000021023 sodium intake Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940057613 veratrum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62031233A JPS63198629A (ja) | 1987-02-13 | 1987-02-13 | 高血圧予防・治療剤 |
| US07/155,509 US4983582A (en) | 1987-02-13 | 1988-02-12 | Preventive and therapeutic method for hypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP62031233A JPS63198629A (ja) | 1987-02-13 | 1987-02-13 | 高血圧予防・治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS63198629A JPS63198629A (ja) | 1988-08-17 |
| JPH0521089B2 true JPH0521089B2 (enExample) | 1993-03-23 |
Family
ID=12325691
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62031233A Granted JPS63198629A (ja) | 1987-02-13 | 1987-02-13 | 高血圧予防・治療剤 |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US4983582A (enExample) |
| JP (1) | JPS63198629A (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5356879A (en) * | 1992-02-14 | 1994-10-18 | Biospherics, Incorporated | D-tagatose as anti-hyperglycemic agent |
| US8440619B2 (en) * | 2005-08-31 | 2013-05-14 | National University Corporation Kagawa University | Utilization of hypertension/hypercardia-preventing effect of D-allose |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1351134A (fr) * | 1962-03-15 | 1964-01-31 | Colonial Sugar Refining Co | Procédé de fabrication d'esters phosphoriques d'hydrates de carbone et d'alcools polyhydriques |
| FR3096M (fr) * | 1963-07-09 | 1965-02-01 | Roussel Uclaf | Nouveau médicament notamment pour le traitement des états d'adynamie. |
| DE1468875A1 (de) * | 1964-06-24 | 1970-10-22 | Roussel Uclaf | Verfahren zur Herstellung eines neuen Salzes der Glucose-1-phosphorsaeure |
| GB1134062A (en) * | 1964-11-25 | 1968-11-20 | Colonial Sugar Refining Co | Water-soluble phosphate compositions and process for preparing |
| FR5145M (enExample) * | 1966-05-03 | 1967-06-05 | ||
| SU454911A1 (ru) * | 1969-11-19 | 1974-12-30 | Ленинградский Ордена Трудового Красного Знамени Научно-Исследовательский Институт Гематологии И Переливания Крови | Средство, повышающее уровень энергетического обмена организма "гексозофосфат" |
| US4006134A (en) * | 1970-09-07 | 1977-02-01 | Imperial Chemical Industries Limited | Calcium sugar phosphates |
| US3931402A (en) * | 1970-12-02 | 1976-01-06 | Societa Prodotti Antibiotici S.P.A. | Preparations containing hexoses |
| BE794136A (fr) * | 1972-01-19 | 1973-07-17 | Roussel Uclaf | Procede de preparation de sels de l'acide alpha-d-glucose-1- phosphorique et produits obtenus |
| DE2518888C3 (de) * | 1975-04-28 | 1980-07-03 | Lentia Gmbh, Chem. U. Pharm. Erzeugnisse - Industriebedarf, 8000 Muenchen | Verwendung einer Infusionslösung bestimmter Zusammensetzung bei der Therapie mittels forcierter Diurese |
| DE2629845A1 (de) * | 1976-07-02 | 1978-01-05 | Geb Graze Erika Graze | Infusions- bzw. injektionsloesungen bzw. waessrige konzentrate zu deren bereitung zur therapeutischen restituion des zellulaeren energiestoffwechsels und der koerpereigenen regelfunktion |
| JPS57145899A (en) * | 1981-03-05 | 1982-09-09 | Wakunaga Yakuhin Kk | Steroid saponin and its preparation |
| JPS60130523A (ja) * | 1983-12-16 | 1985-07-12 | Yamasa Shoyu Co Ltd | アルギン酸カルシウムを有効成分とする経口医療補助組成物 |
-
1987
- 1987-02-13 JP JP62031233A patent/JPS63198629A/ja active Granted
-
1988
- 1988-02-12 US US07/155,509 patent/US4983582A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US4983582A (en) | 1991-01-08 |
| JPS63198629A (ja) | 1988-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1089726B1 (en) | Composition comprising ss-hydroxy-ss-methylbutyric acid and at least one amino acid | |
| RU2163487C2 (ru) | Применение продуктов на основе магния для лечения или профилактики опухолевых и аутоиммунных заболеваний | |
| US5182112A (en) | Antidiarrheal compositions containing laperamide hydrochloride and a saccharide | |
| Horwitz et al. | A non-hydrazine monoamine oxidase inhibitor with antihypertensive properties | |
| EP0055118A1 (en) | Arthritis treatment | |
| JP3622985B2 (ja) | マグネシウム吸収を高め、アテローム性動脈硬化症を防ぐ方法 | |
| AU634988B2 (en) | Treatment of hypertension | |
| JPH0521089B2 (enExample) | ||
| US5466713A (en) | Iloprost with action against cerebral malaria | |
| EP1362593B1 (en) | Cytidine-phosphocholine for the treatment of diabetic neuropathy | |
| US5348749A (en) | Method for treating panic disorder | |
| US4298611A (en) | Process for reducing blood pressure in animals | |
| US5498428A (en) | Treatment of hypertension by oral administration of potassium bicarbonate | |
| EP0342211B1 (en) | Treatment of arteriosclerosis by administration of l-tryptophan or l-5-hydroxytryptophan | |
| GB1584089A (en) | Antihypertensive pharmaceutical compositions | |
| KR100816140B1 (ko) | 일차성 두통의 치료에서 비타민 혼합물의 용도 | |
| Ogihara et al. | Dose-effect relationship of carvedilol in essential hypertension: an open study | |
| Bloomfield et al. | Guanadrel and guanethidine in hypertension | |
| JPH11171763A (ja) | 肝疾患治療剤 | |
| Svedmyr et al. | Effects of sotalol and propranolol administered orally in man | |
| JPH0333715B2 (enExample) | ||
| JPH0235057A (ja) | 機能性食品 | |
| US4156003A (en) | Treatment of hypertension with combination of clofibrinic acid or clofibrate with cinnarizine | |
| EP0759298B1 (en) | Use of 4-amino-6-hydroxypyrazolo[3,4-d]pyrimidine for the manufacture of an antihypertensive agent | |
| JPH0237326B2 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |